- Symbiosis Pharmaceutical Services has qualified a new automated sterile fill/finish line at its Stirling commercial production facility in Scotland.
- The company will begin commercial production in Q4 2025, with the capacity to manufacture up to 15,000 vials per batch.
Symbiosis Pharmaceutical Services has completed the qualification of its new FPD 50 Flexicon automated fill/finish line at its commercial production facility in Stirling, Scotland. The fully integrated system, operating under a Grade A Restricted Access Barrier System (RABS), is designed for aseptic handling and high-precision vial filling.
The line incorporates flexicon pump technology, rapid transfer ports, and a rotary crimp mechanism to ensure secure vial closure. With these features, the company aims to increase efficiency and meet growing demand for sterile injectable drug product manufacturing.
“The qualification of our automated fill/finish line is a major step forward for Symbiosis. It enhances our technical capabilities and expands our capacity at a time when demand for high-quality sterile manufacturing continues to grow. Most importantly, it strengthens our ability to help clients bring vital therapies to patients quickly and to the highest regulatory standards.”
Colin MacKay, CEO of Symbiosis
Commercial production at the new facility is scheduled to commence in Q4 2025, with the capacity to produce batches of up to 15,000 vials. The development follows a series of recent milestones for the company, including manufacturing its 1,000th sterile batch in July 2025 and receiving the UK 2025 King’s Award for Enterprise in International Trade.
Founded over 14 years ago, Symbiosis has maintained a strong record of GMP compliance with both the FDA and MHRA. The company supported clinical development of the Oxford University/AstraZeneca COVID-19 vaccine and continues to expand its global presence by delivering sterile injectable products across diverse drug modalities and therapeutic areas.
